Announcements Trials
Browse Landscape

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 20Observational 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Burkitt Lymphoma 2Recurrence 1Hematologic Neoplasms 1

Interventions

Sunitinib 16exemestane 11Afatinib 11palbociclib 10Rituximab 10Bevacizumab 10Erlotinib Hydrochloride 9Leuprolide 8Radiotherapy 7Drug Therapy 7Axitinib 7avelumab 6Letrozole 6Capecitabine 6Blood Specimen Collection 6enzalutamide 5Trastuzumab 5Surveys and Questionnaires 5Standard of Care 5Docetaxel 5Aromatase Inhibitors 5lorlatinib 4Specimen Handling 4Radiation 4Mammography 4Crizotinib 4Anastrozole 4Abiraterone Acetate 4temsirolimus 3talazoparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Has results × Inotuzumab Ozogamicin × Clear all
NCT04307134 2025-12-31

Besponsa Post Marketing Surveillance Study

Pfizer

Completed
108 enrolled 39 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hematologic Neoplasms

NCT05597085 2025-02-04

A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment

Pfizer

Completed
32 enrolled 31 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04456959 2022-09-28

InO

Pfizer

Completed
28 enrolled 55 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡